83 results on '"Venneri, Ma"'
Search Results
2. Proangiogenic Tie²⁺ macrophages infiltrate human and murine endometriotic lesions and dictate their growth in a mouse model of the disease
- Author
-
Capobianco A, Monno A, Cottone L, Venneri MA, Biziato D, Di Puppo F, Ferrari S, De Palma M, MANFREDI , ANGELO ANDREA M. A., ROVERE QUERINI , PATRIZIA, Capobianco, A, Monno, A, Cottone, L, Venneri, Ma, Biziato, D, Di Puppo, F, Ferrari, S, De Palma, M, Manfredi, ANGELO ANDREA M. A., and ROVERE QUERINI, Patrizia
- Published
- 2011
3. Systemic and targeted delivery of Sema3A inhibits tumor angiogenesis and tumor progression
- Author
-
Casazza A, Fu X, Johansson I, Capparuccia L, Andersson F, Giustacchini A, Squadrito ML, Venneri MA, Mazzone M, Larsson E, Carmeliet P, De Palma M, Naldini L, Tamagnone L, and Rolny C
- Published
- 2011
4. Tie2 identifies a hematopoietic monocytes required for tumor lineage of proangiogenic vessel formation and a mesenchymal population of pericyte progenitors
- Author
-
De Palma, M, Venneri, MA, Galli, R, Sergi, LS, Politi, LS, Sampaolesi, Maurilio, and Naldini, L
- Subjects
Marrow-Derived Cells ,Stem-Cells ,Endothelial-Cells ,Lentiviral Vectors ,Vascularization ,Precursors ,Angiogenesis ,Growth ,In-Vivo ,Vegf - Abstract
Bone marrow-derived cells contribute to tumor angiogenesis. Here, we demonstrate that monocytes expressing the Tie2 receptor (Tie2-expressing monocytes [TEMs]) (1) are a distinct hematopoietic lineage of proangiogenic cells, (2) are selectively recruited to spontaneous and orthotopic tumors, (3) promote angiogenesis in a paracrine manner, and (4) account for most of the proangiogenic activity of myeloid cells in tumors. Remarkably, TEM knockout completely prevented human glioma neovascularization in the mouse brain and induced substantial tumor regression. Besides TEMs and endothelial cells (ECs), Tie2 expression distinguished a rare population of tumor stroma-derived mesenchymal progenitors representing a primary source of tumor pericytes. Therefore, Tie2 expression characterizes three distinct cell types required for tumor neovascularization: ECs, proangiogenic cells of hematopoietic origin, and pericyte precursors of mesenchymal origin. ispartof: Cancer Cell vol:8 issue:3 pages:211-226 ispartof: location:United States status: published
- Published
- 2005
5. From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?
- Author
-
Giulia Puliani, Andrea Lania, Fabio Lo Calzo, Valentina Guarnotta, Giuseppe Fanciulli, Alessandra Dicitore, Carmen Rainone, Annamaria Colao, Genoveffa Pizza, Manila Rubino, Giovanni Vitale, Severo Campione, Francesco Ferraù, Maria Chiara Zatelli, Mary Anna Venneri, Emilia Sbardella, Diego Ferone, Marco Gallo, Riccardo Pofi, Roberta Modica, Luigi Barrea, Erika Grossrubatscher, Federica Grillo, Antongiulio Faggiano, Franz Sesti, Rosa Maria Ruggieri, Barbara Altieri, Erika Messina, Luca Pes, P. Razzore, Nike, Andrea M. Isidori, Sergio Di Molfetta, Pasquale Malandrino, Andrea Lenzi, Manuela Albertelli, Tiziana Feola, Laura Rizza, Giovanna Muscogiuri, Federica de Cicco, Filomena Bottiglieri, Elia Guadagno, Elisa Giannetta, Vitale G, Dicitore A, Barrea L, Sbardella E, Razzore P, Campione S, Faggiano A, Colao A, NIKE, Albertelli M, Altieri B, Bottiglieri F, De Cicco F, Di Molfetta S, Fanciulli G, Feola T, Ferone D, Ferraù F, Gallo M, Giannetta E, Grillo F, Grossrubatscher E, Guadagno E, Guarnotta V, Isidori AM, Lania A, Lenzi A, Calzo FL, Malandrino P, Messina E, Modica R, Muscogiuri G, Pes L, Pizza G, Pofi R, Puliani G, Rainone C, Rizza L, Rubino M, Ruggieri RM, Sesti F, Venneri MA, Zatelli MC., Vitale, G., Dicitore, A., Barrea, L., Sbardella, E., Razzore, P., Campione, S., Faggiano, A., Colao, A., Albertelli, M., Altieri, B., Bottiglieri, F., De Cicco, F., Di Molfetta, S., Fanciulli, G., Feola, T., Ferone, D., Ferrau, F., Gallo, M., Giannetta, E., Grillo, F., Grossrubatscher, E., Guadagno, E., Guarnotta, V., Isidori, A. M., Lania, A., Lenzi, A., Calzo, F. L., Malandrino, P., Messina, E., Modica, R., Muscogiuri, G., Pes, L., Pizza, G., Pofi, R., Puliani, G., Rainone, C., Rizza, L., Rubino, M., Ruggieri, R. M., Sesti, F., Venneri, M. A., and Zatelli, M. C.
- Subjects
Endocrinology, Diabetes and Metabolism ,Tumor microenvironment ,Biology ,Gut flora ,Neuroendocrine tumors ,medicine.disease_cause ,digestive system ,Article ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Immune system ,Neuroendocrine tumor ,Gastro ,medicine ,Humans ,Cytokine ,030304 developmental biology ,Gastrointestinal Neoplasms ,Inflammation ,0303 health sciences ,Microbiota ,digestive, oral, and skin physiology ,medicine.disease ,biology.organism_classification ,Cytokines ,Gastrointestinal Microbiome ,030220 oncology & carcinogenesis ,Immunology ,Dysbiosis ,Carcinogenesis ,Drug metabolism - Abstract
Gut microbiota is represented by different microorganisms that colonize the intestinal tract, mostly the large intestine, such as bacteria, fungi, archaea and viruses. The gut microbial balance has a key role in several functions. It modulates the host’s metabolism, maintains the gut barrier integrity, participates in the xenobiotics and drug metabolism, and acts as protection against gastro-intestinal pathogens through the host’s immune system modulation. The impaired gut microbiota, called dysbiosis, may be the result of an imbalance in this equilibrium and is linked with different diseases, including cancer. While most of the studies have focused on the association between microbiota and gastrointestinal adenocarcinomas, very little is known about gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs). In this review, we provide an overview concerning the complex interplay between gut microbiota and GEP NENs, focusing on the potential role in tumorigenesis and progression in these tumors.
- Published
- 2020
6. Epidemiology of pancreatic neuroendocrine neoplasms. a gender perspective
- Author
-
Muscogiuri, G., Altieri, B., Albertelli, M., Dotto, A., Modica, R., Barrea, L., Fanciulli, G., Feola, T., Baldelli, R., Ruggeri, R. M., Gallo, M., Guarnotta, V., Malandrino, P., Messina, E., Venneri, M. A., Giannetta, E., Ferone, D., Colao, A., Faggiano, A., Bottiglieri, F., Campione, S., de Cicco, F., Dicitore, A., Ferrau, F., Grillo, F., Grossrubatscher, E., Guadagno, E., Isidori, A. M., Lania, A., Lenzi, A., Calzo, F. L., Pes, L., Pizza, G., Pofi, R., Puliani, G., Rainone, C., Razzore, P., Rizza, L., Rubino, M., Sbardella, E., Sesti, F., Vitale, G., Zatelli, M. C., Muscogiuri G, Altieri B, Albertelli M, Dotto A, Modica R, Barrea L, Fanciulli G, Feola T, Baldelli R, Ruggeri RM, Gallo M, Guarnotta V, Malandrino P, Messina E, Venneri MA, Giannetta E, Ferone D, Colao A, Faggiano A, Muscogiuri, G., Altieri, B., Albertelli, M., Dotto, A., Modica, R., Barrea, L., Fanciulli, G., Feola, T., Baldelli, R., Ruggeri, R. M., Gallo, M., Guarnotta, V., Malandrino, P., Messina, E., Venneri, M. A., Giannetta, E., Ferone, D., Colao, A., Faggiano, A., Bottiglieri, F., Campione, S., de Cicco, F., Dicitore, A., Ferrau, F., Grillo, F., Grossrubatscher, E., Guadagno, E., Isidori, A. M., Lania, A., Lenzi, A., Calzo, F. L., Pes, L., Pizza, G., Pofi, R., Puliani, G., Rainone, C., Razzore, P., Rizza, L., Rubino, M., Sbardella, E., Sesti, F., Vitale, G., and Zatelli, M. C.
- Subjects
Male ,medicine.medical_specialty ,Cardiovascular diseases ,Epidemiology ,Gender ,Pancreatic neuroendocrine neoplasms ,Sex ,Type 2 diabetes ,Female ,Humans ,Middle Aged ,Pancreas ,Retrospective Studies ,Diabetes Mellitus, Type 2 ,Neuroendocrine Tumors ,Pancreatic Neoplasms ,Pancreatic neuroendocrine neoplasm ,Endocrinology, Diabetes and Metabolism ,030209 endocrinology & metabolism ,Disease ,Neuroendocrine tumors ,Type 2 diabete ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Retrospective Studie ,Internal medicine ,Diabetes mellitus ,medicine ,gender ,Pancrea ,sex ,business.industry ,pancreatic neuroendocrine neoplasms ,Retrospective cohort study ,medicine.disease ,Cardiovascular disease ,cardiovascular diseases ,Natural history ,030220 oncology & carcinogenesis ,Pancreatitis ,epidemiology ,type 2 diabetes ,business ,Neuroendocrine Tumor ,Human - Abstract
Purpose: Pancreatic neuroendocrine neoplasms (PNENs) are a group of clinically rare and heterogeneous tumors of the pancreas. Currently there are no studies investigating the gender difference in PNEN susceptibility. Thus, the purpose of this study was aimed at examining how gender shapes risk factors, clinicopathological features, and comorbidities in PNENs. Methods: The study design consisted of an Italian multicenter, retrospective study. The study included all consecutive patients with PNENs followed at the participating centers. Two hundred and twenty-nine patients (105 males,124 females, age 54 ± 0.98 years) with PNENs were enrolled at the participating centers. The clinicopathological features (age, gender, BMI, histology, tumor size, tumor grade, distant metastasis, hormonal function, and diagnostic circumstances), comorbidities (cardiovascular diseases (CVD), pancreatitis, type 2 diabetes (T2DM), and potential risk factors (smoking and drinking) were included in the analysis. Results: Females were slightly prevalent (54.15%). PNENs were diagnosed at younger age in females compared to males (p = 0.04). The prevalence of CVD was significantly higher in males than in females (p = 0.006). In the female group, the presence of T2DM was significantly associated with higher tumor grade (p = 0.04) and metastatic disease (p = 0.02). The proportion of smokers and alcohol drinkers was significantly higher in the male group (p < 0.001). No significant gender differences were detected regarding the other parameters included in the analysis. Conclusions: This study has identified gender differences of PNENs in terms of age at diagnosis, associated comorbidities, and potential risk factors. A gender-tailored approach could become a potential strategy to better understand the natural history of PNENs and improve the effectiveness of PNENs clinical management.
- Published
- 2020
7. Systemic and Targeted Delivery of Semaphorin 3A Inhibits Tumor Angiogenesis and Progression in Mouse Tumor Models
- Author
-
Luigi Naldini, Michele De Palma, Mary Anna Venneri, Alice Giustacchini, Xi Fu, Irja Johansson, Andrea Casazza, Lorena Capparuccia, Luca Tamagnone, Mario Leonardo Squadrito, Peter Carmeliet, Fredrik Andersson, Erik G. Larsson, Massimiliano Mazzone, Charlotte Rolny, Casazza, A, Fu, X, Johansson, I, Capparuccia, L, Andersson, F, Giustacchini, A, Squadrito, Ml, Venneri, Ma, Mazzone, M, Larsson, E, Carmeliet, P, De Palma, M, Naldini, Luigi, Tamagnone, L, and Rolny, C.
- Subjects
Pathology ,semaphorins ,Lung Neoplasms ,Time Factors ,CD30 ,neuropilins ,Angiogenesis ,semaphorin ,Metastasis ,Mice ,angiogenesis ,0302 clinical medicine ,Cell Movement ,Receptors ,Neuropilin ,molecular biology ,metastasis ,neuropilin ,pathology ,receptors ,tumor ,vascular biology ,Cardiology and Cardiovascular Medicine ,Mice, Inbred BALB C ,0303 health sciences ,Tumor ,Neovascularization, Pathologic ,Stem Cells ,Hematopoietic Stem Cell Transplantation ,Receptor, TIE-2 ,Primary tumor ,Cell Hypoxia ,Tumor Burden ,030220 oncology & carcinogenesis ,embryonic structures ,Female ,RNA Interference ,Settore BIO/17 - ISTOLOGIA ,biological phenomena, cell phenomena, and immunity ,Signal Transduction ,medicine.medical_specialty ,animal structures ,Recombinant Fusion Proteins ,Breast Neoplasms ,Biology ,Transfection ,Necrosis ,03 medical and health sciences ,Semaphorin ,Cell Line, Tumor ,Paracrine Communication ,medicine ,Animals ,Humans ,Cell Proliferation ,030304 developmental biology ,Tumor hypoxia ,Semaphorin-3A ,Genetic Therapy ,medicine.disease ,Xenograft Model Antitumor Assays ,Neuropilin-1 ,nervous system ,Tumor progression ,Cancer research ,sense organs ,Stromal Cells - Abstract
Objective— The role of semaphorins in tumor progression is still poorly understood. In this study, we aimed at elucidating the regulatory role of semaphorin 3A (SEMA3A) in primary tumor growth and metastatic dissemination. Methods and Results— We used 3 different experimental approaches in mouse tumor models: (1) overexpression of SEMA3A in tumor cells, (2) systemic expression of SEMA3A following liver gene transfer in mice, and (3) tumor-targeted release of SEMA3A using gene modified Tie2-expressing monocytes as delivery vehicles. In each of these experimental settings, SEMA3A efficiently inhibited tumor growth by inhibiting vessel function and increasing tumor hypoxia and necrosis, without promoting metastasis. We further show that the expression of the receptor neuropilin-1 in tumor cells is required for SEMA3A-dependent inhibition of tumor cell migration in vitro and metastatic spreading in vivo. Conclusion— In sum, both systemic and tumor-targeted delivery of SEMA3A inhibits tumor angiogenesis and tumor growth in multiple mouse models; moreover, SEMA3A inhibits the metastatic spreading from primary tumors. These data support the rationale for further investigation of SEMA3A as an anticancer molecule.
- Published
- 2011
8. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer
- Author
-
Luigi Naldini, Maurilio Ponzoni, Cristina Scielzo, Ferdinando Pucci, Erika Zonari, Mary Anna Venneri, Claudio Doglioni, Michele De Palma, Roberta Mazzieri, Venneri, Ma, De Palma, M, Ponzoni, Maurilio, Pucci, F, Scielzo, C, Zonari, E, Mazzieri, R, Doglioni, Claudio, and Naldini, Luigi
- Subjects
Angiogenesis ,Immunology ,Population ,Neovascularization, Physiologic ,Biochemistry ,Peripheral blood mononuclear cell ,Monocytes ,Angiopoietin-2 ,Neovascularization ,Neoplasms ,medicine ,Humans ,Angiogenic Proteins ,education ,education.field_of_study ,Blood Cells ,Neovascularization, Pathologic ,biology ,Monocyte ,Cancer ,Cell Biology ,Hematology ,medicine.disease ,Receptor, TIE-2 ,Angiopoietin receptor ,Chemotaxis, Leukocyte ,medicine.anatomical_structure ,Tumor progression ,biology.protein ,medicine.symptom - Abstract
Tumor-infiltrating myeloid cells, including tumor-associated macrophages (TAMs), have been implicated in tumor progression. We recently described a lineage of mouse monocytes characterized by expression of the Tie2 anglopoletin receptor and required for the vascularization and growth of several tumor models. Here, we report that TIE2 expression in human blood identifies a subset of monocytes distinct from classical inflammatory monocytes and comprised within the less abundant "resident" population. These TIE2-expressing monocytes (TEMs) accounted for 2% to 7% of blood mononuclear cells in healthy donors and were distinct from rare circulating enclothelial cells and progenitors. In human cancer patients, TEMs were observed in the blood and, intriguingly, within the tumors, where they represented the main monocyte population distinct from TAMs. Conversely, TEMs were hardly detected in nonneoplastic tissues. In vitro, TEMs migrated toward angiopoietin-2, a TIE2 Iigand released by activated enclothelial cells and anglogenic vessels, suggesting a homing mechanism for TEMs to tumors. Purified human TEMs, but not TEM-clepleted monocytes, markedly promoted angiogenesis in xenotransplanted human tumors, suggesting a potentially critical role of TEMs in human cancer progression. Human TEMs may provide a novel, biologically relevant marker of angiogenesis and represent a previously unrecognized target of cancer therapy. Tumor-infiltrating myeloid cells, including tumor-associated macrophages (TAMs), have been implicated in tumor progression. We recently described a lineage of mouse monocytes characterized by expression of the Tie2 anglopoletin receptor and required for the vascularization and growth of several tumor models. Here, we report that TIE2 expression in human blood identifies a subset of monocytes distinct from classical inflammatory monocytes and comprised within the less abundant "resident" population. These TIE2-expressing monocytes (TEMs) accounted for 2% to 7% of blood mononuclear cells in healthy donors and were distinct from rare circulating enclothelial cells and progenitors. In human cancer patients, TEMs were observed in the blood and, intriguingly, within the tumors, where they represented the main monocyte population distinct from TAMs. Conversely, TEMs were hardly detected in nonneoplastic tissues. In vitro, TEMs migrated toward angiopoietin-2, a TIE2 Iigand released by activated enclothelial cells and anglogenic vessels, suggesting a homing mechanism for TEMs to tumors. Purified human TEMs, but not TEM-clepleted monocytes, markedly promoted angiogenesis in xenotransplanted human tumors, suggesting a potentially critical role of TEMs in human cancer progression. Human TEMs may provide a novel, biologically relevant marker of angiogenesis and represent a previously unrecognized target of cancer therapy.
- Published
- 2007
9. In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors
- Author
-
Luigi Naldini, Michele De Palma, Mary Anna Venneri, De Palma, M, Venneri, Ma, and Naldini, Luigi
- Subjects
Transcription, Genetic ,Angiogenesis ,Swine ,Genetic enhancement ,Genetic Vectors ,Biology ,Regulatory Sequences, Nucleic Acid ,Vesicular stomatitis Indiana virus ,Transduction (genetics) ,Mice ,Transduction, Genetic ,Proto-Oncogene Proteins ,Genetics ,Tumor Cells, Cultured ,Animals ,Humans ,Microscopy, Phase-Contrast ,Endothelium ,Enhancer ,Molecular Biology ,Cells, Cultured ,Phosphoglycerate kinase ,Genetic transfer ,Lentivirus ,Neoplasms, Experimental ,Molecular biology ,Receptor, TIE-2 ,Vascular Endothelial Growth Factor Receptor-2 ,Cell biology ,Neoplasm Proteins ,Endothelial stem cell ,Microscopy, Fluorescence ,Regulatory sequence ,Injections, Intravenous ,Molecular Medicine - Abstract
Tumor angiogenesis is a rate-limiting factor for tumor growth, and the endothelial cells of tumor vessels display specific features that can be exploited for the selective delivery of cancer therapeutics. To specifically target exogenous genes to angiogenic tumor vessels, we generated a panel of vesicular stomatitis virus-pseudotyped lentiviral vectors (LVs) engineered for endothelial cell (EC)-specific expression. We cloned a wide repertoire of transcription regulatory sequences from genes preferentially expressed in ECs (Tie1, Tie2, Flk-1, VE-Cad, and ICAM-2) into self-inactivating LVs to drive expression of the marker gene encoding green fluorescent protein (GFP) or of the conditionally toxic gene encoding nitroreductase, and compared them with the ubiquitously expressing phosphoglycerate kinase (PGK) and cytomegalovirus (CMV) promoters. We evaluated the efficiency and specificity of vector expression in vitro in a panel of human primary cultures, including ECs, fibroblasts, neurons, lymphocytes, and hematopoietic progenitors, and in tumor cell lines. We found that vectors containing promoter and enhancer sequences from the Tie2 gene achieved remarkable specificity of expression in ECs in vitro and in vivo. On intravenous delivery into tumor-bearing mice, the Tie2 vector targeted expression to the ECs of tumor vessels. In contrast, LVs carrying the PGK or CMV promoter gave widespread GFP marking in ECs and non-ECs of tumors and other organs. The previously reported upregulation of the Tie2 gene in ECs activated for angiogenesis may explain the remarkable selectivity of expression of the Tie2 vector in ECs of tumor vessels. The new vector provides the means for selective delivery of gene therapy to tumor sites in vivo.
- Published
- 2003
10. Correction: Notch3-regulated microRNAs impair CXCR4-dependent maturation of thymocytes allowing maintenance and progression of T-ALL.
- Author
-
Sergio I, Varricchio C, Patel SK, Del Gaizo M, Russo E, Orlando A, Peruzzi G, Ferrandino F, Tsaouli G, Coni S, Peluso D, Besharat ZM, Campolo F, Venneri MA, Del Bufalo D, Lai S, Indraccolo S, Minuzzo S, La Starza R, Bernardini G, Screpanti I, Campese AF, and Felli MP
- Published
- 2024
- Full Text
- View/download PDF
11. Notch3-regulated microRNAs impair CXCR4-dependent maturation of thymocytes allowing maintenance and progression of T-ALL.
- Author
-
Sergio I, Varricchio C, Patel SK, Del Gaizo M, Russo E, Orlando A, Peruzzi G, Ferrandino F, Tsaouli G, Coni S, Peluso D, Besharat ZM, Campolo F, Venneri MA, Del Bufalo D, Lai S, Indraccolo S, Minuzzo S, La Starza R, Bernardini G, Screpanti I, Campese AF, and Felli MP
- Subjects
- Animals, Mice, Humans, Mice, Transgenic, Signal Transduction, Cell Differentiation genetics, MicroRNAs genetics, MicroRNAs metabolism, Receptor, Notch3 genetics, Receptor, Notch3 metabolism, Thymocytes metabolism, Thymocytes cytology, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma pathology, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma genetics, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma metabolism, Receptors, CXCR4 metabolism, Receptors, CXCR4 genetics, Disease Progression
- Abstract
Malignant transformation of T-cell progenitors causes T-cell acute lymphoblastic leukemia (T-ALL), an aggressive childhood lymphoproliferative disorder. Activating mutations of Notch, Notch1 and Notch3, have been detected in T-ALL patients. In this study, we aimed to deeply characterize hyperactive Notch3-related pathways involved in T-cell dynamics within the thymus and bone marrow to propose these processes as an important step in facilitating the progression of T-ALL. We previously generated a transgenic T-ALL mouse model (N3-ICtg) demonstrating that aberrant Notch3 signaling affects early thymocyte maturation programs and leads to bone marrow infiltration by CD4
+ CD8+ (DP) T cells that are notably, Notch3high CXCR4high . Newly, our in vivo results suggest that an anomalous immature thymocyte subpopulation, such as CD4- CD8- (DN) over-expressing CD3ɛ, but with low CXCR4 expression, dominates N3-ICtg thymus-resident DN subset in T-ALL progression. MicroRNAs might be of significance in T-ALL pathobiology, however, whether required for leukemia maintenance is not fully understood. The selection of specific DN subsets demonstrates the inverse correlation between CXCR4 expression and a panel of Notch3-deregulated miRNAs. Interestingly, we found that within DN thymocyte subset hyperactive Notch3 inhibits CXCR4 expression through the cooperative effects of miR-139-5p and miR-150-5p, thus impinging on thymocyte differentiation with accumulation of DNCD3ɛ+ CXCR4- cells. These data point out that deregulation of Notch3 in T-ALL, besides its role in sustaining dissemination of abnormal DP T cells, as we previously demonstrated, could play a role in selecting specific DN immature T cells within the thymus, thus impeding T cell development, to facilitate T-ALL progression inside the bone marrow., (© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)- Published
- 2024
- Full Text
- View/download PDF
12. A pathogenic role for brain-derived neurotrophic factor (BDNF) in fibrous dysplasia of bone.
- Author
-
Palmisano B, Farinacci G, Campolo F, Tavanti C, Stefano A, Donsante S, Ippolito E, Giannicola G, Venneri MA, Corsi A, and Riminucci M
- Subjects
- Humans, Mice, Animals, Brain-Derived Neurotrophic Factor, Bone and Bones metabolism, Osteoclasts metabolism, Fibrous Dysplasia of Bone genetics, Bone Resorption
- Abstract
Brain derived neurotrophic factor (BDNF) is a neurotrophin, expressed in the central nervous system and in peripheral tissues, that is regulated by the Gsα/cAMP pathway. In bone, it regulates osteogenesis and stimulates RANKL secretion and osteoclast formation in osteolytic tumors such as Multiple Myeloma. Fibrous dysplasia (FD) of bone is a rare genetic disease of the skeleton caused by gain-of-function mutations of the Gsα gene in which RANKL-dependent enhanced bone resorption is a major cause of bone fragility and clinical morbidity. We observed that BDNF transcripts are expressed in human FD lesions. Specifically, immunolocalization studies performed on biopsies obtained from FD patients revealed the expression of BDNF in osteoblasts and, to a lower extent, in the spindle-shaped cells within the fibrous tissue. Therefore, we hypothesized that BDNF can play a role in the pathogenesis of FD by stimulating RANKL secretion and bone resorption. To test this hypothesis, we used the EF1α-Gsα
R201C mouse model of the human disease (FD mice). Western blot analysis revealed a higher expression of BDNF in bone segments of FD mice compared to WT mice and the immunolabeling pattern within mouse FD lesions was similar to that observed in human FD. Treatment of FD mice with a monoclonal antibody against BDNF reduced the fibrous tissue along with the number of osteoclasts and osteoblasts within femoral lesions. These results reveal BDNF as a new player in the pathogenesis of FD and a potential molecular mechanism by which osteoclastogenesis may be nourished within FD bone lesions. They also suggest that BDNF inhibition may be a new approach to reduce abnormal bone remodeling in FD., Competing Interests: Declaration of competing interest The authors declare that they have no conflicts of interest to declare., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
13. Exploring sexual function in adrenal insufficiency: findings from the Dual RElease hydrocortisone versus conventionAl glucocorticoid replaceMent therapy in hypocortisolism (DREAM) trial.
- Author
-
Hasenmajer V, De Alcubierre D, Ferrari D, Minnetti M, Bonaventura I, Pofi R, Simeoli C, Tomaselli A, Sciarra F, Bottillo G, Angelini F, Cozzolino A, Venneri MA, Jannini EA, Gianfrilli D, Pivonello R, and Isidori AM
- Abstract
Background: Data on sexual function in patients with adrenal insufficiency are scarce and largely controversial., Objectives: To investigate sexual dysfunction in patients with primary and secondary adrenal insufficiency and the effects of switching to once-daily dual-release hydrocortisone on sexual function in outcome assessors blinded, randomized, multicenter, active comparator clinical trial., Materials and Methods: Eighty-nine adrenal insufficiency patients on conventional, multiple daily doses of glucocorticoid replacement, enrolled in the Dual RElease hydrocortisone versus conventionAl glucocorticoid replaceMent in hypocortisolism (DREAM) trial, were randomly assigned to continue their therapy or to switch to an equivalent dose of dual-release hydrocortisone. Sixty-three patients (34 women) consented to sex steroid measurements and questionnaires completion for quality of life (Addison's disease-specific quality-of-life questionnaire) and sexual function evaluation (female sexual function index for women, International Index of Erectile Function-Erectile Function for men) at baseline and 24 weeks after randomization., Results: At baseline, sexual dysfunction was observed in 41% of women and 59% of men with adrenal insufficiency. In both sexes, no associations were found between sexual function and hormone levels, whereas Addison's disease-specific quality-of-life questionnaire total and fatigue domain scores positively correlated with total female sexual function index and International Index of Erectile Function-Erectile Function scores. At 24 weeks, there was no significant difference either in sexual function or sex steroid levels between study groups. In the dual-release hydrocortisone group, the variation in the female sexual function index desire domain score was positively associated with the change in Addison's disease-specific quality-of-life questionnaire's symptom domain score (ρ = 0.478, p = 0.045)., Discussion: Sexual dysfunction is common in adrenal insufficiency patients and is likely explained by multiple factors. dual-release hydrocortisone treatment is not directly associated with sexual function improvement, but an indirect effect mediated by quality-of-life amelioration cannot be excluded., (© 2024 The Authors. Andrology published by Wiley Periodicals LLC on behalf of American Society of Andrology and European Academy of Andrology.)
- Published
- 2024
- Full Text
- View/download PDF
14. Clinical management of androgen excess and defect in women.
- Author
-
Rosato E, Sciarra F, Minnetti M, Degjoni A, and Venneri MA
- Subjects
- Adolescent, Female, Humans, Androgens therapeutic use, Testosterone therapeutic use, Estrogens, Hyperandrogenism drug therapy, Polycystic Ovary Syndrome complications, Polycystic Ovary Syndrome drug therapy, Polycystic Ovary Syndrome diagnosis
- Abstract
Introduction: Hyperandrogenism and hypoandrogenism are complex disorders involving multiple-organ systems. While androgen excess is a well-characterized condition, androgen deficiency still needs diagnostic criteria, as there are no specific cutoffs., Areas Covered: We highlight the most recent findings on the role of androgens in female pathophysiology, investigating clinically relevant conditions of androgen insufficiency or excess throughout a woman's life, and their possible therapeutic management., Expert Opinion: Combined oral contraceptives (COCs) should be considered as first-line therapy for the management of menstrual irregularity and/or clinical hyperandrogenism in adolescents with a clear diagnosis of polycystic ovary syndrome (PCOS). There are limited evidence-based data regarding specific types or doses of COCs for management of PCOS in women; however, the lowest effective estrogen dose should be considered for treatment. Despite evidence regarding safety, efficacy, and clinical use, testosterone therapy has not been approved for women by most regulatory agencies for treatment of hypoactive sexual desire disorder (HSDD). The long-term safety for treatments with testosterone is still to be evaluated, and this review highlights the need for more research in this area.
- Published
- 2024
- Full Text
- View/download PDF
15. How Food Choices Impact on Male Fertility.
- Author
-
Pecora G, Sciarra F, Gangitano E, and Venneri MA
- Subjects
- Animals, Male, Humans, Seeds, Fertility, Hormones, Semen Analysis, Diet, Mediterranean
- Abstract
Purpose of Review: Increasing evidence on the significance of nutrition in reproduction is emerging from both animal and human studies, suggesting an association between nutrition and male fertility. Here, we have highlighted the impact of the various food groups on reproductive hormones and on spermatogenesis, and the effects of classical and latest dietary patterns such as Mediterranean diet, Western diet, intermittent fasting, ketogenic diet, and vegan/vegetarian diet on male fertility., Recent Findings: Nutrients are the precursors of molecules involved in various body's reactions; therefore, their balance is essential to ensure the correct regulation of different systems including the endocrine system. Hormones are strongly influenced by the nutritional status of the individual, and their alteration can lead to dysfunctions or diseases like infertility. In addition, nutrients affect sperm production and spermatogenesis, controlling sexual development, and maintaining secondary sexual characteristics and behaviors. The consumption of fruit, vegetables, fish, processed meats, dairy products, sugars, alcohol, and caffeine importantly impact on male fertility. Among dietary patterns, the Mediterranean diet and the Western diet are most strongly associated with the quality of semen. Nutrients, dietary patterns, and hormonal levels have an impact on male infertility. Therefore, understanding how these factors interact with each other is important for strategies to improve male fertility., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
16. Pituitary T1 signal intensity at magnetic resonance imaging is reduced in patients with obesity: results from the CHIASM study.
- Author
-
Puliani G, Sbardella E, Cozzolino A, Sada V, Tozzi R, Andreoli C, Fiorelli M, Di Biasi C, Corallino D, Balla A, Paganini AM, Venneri MA, Lenzi A, Lubrano C, and Isidori AM
- Subjects
- Humans, Prospective Studies, Fibrinogen, Inflammation, Obesity diagnostic imaging, Weight Gain
- Abstract
Background: Despite obesity being well known to be associated with several pituitary hormone imbalances, pituitary appearance in magnetic resonance imaging (MRI) in patients with obesity is understudied., Objective: To evaluate the pituitary volume and signal intensity at MRI in patients with obesity., Methods: This is a prospective study performed in an endocrine Italian referral center (ClinicalTrial.gov Identifier: NCT03458533). Sixty-nine patients with obesity (BMI > 30 kg/m
2 ) and twenty-five subjects without obesity were enrolled. Thirty-three patients with obesity were re-evaluated after 3 years of diet and lifestyle changes, of whom 17 (51.5%) achieved a > 5% loss of their initial body weight, whereas the remaining 16 (48.5%) had maintained or gained weight. Evaluations included metabolic and hormone assessments, DEXA scan, and pituitary MRI. Pituitary signal intensity was quantified by measuring the pixel density using ImageJ software., Results: At baseline, no difference in pituitary volume was observed between the obese and non-obese cohorts. At the 3-year follow-up, pituitary volume was significantly reduced (p = 0.011) only in participants with stable-increased body weight. Furthermore, a significant difference was noted in the mean pituitary intensity of T1-weighted plain and contrast-enhanced sequences between the obese and non-obese cohorts at baseline (p = 0.006; p = 0.002), and a significant decrease in signal intensity was observed in the subgroup of participants who had not lost weight (p = 0.012; p = 0.017). Insulin-like growth factor-1 levels, following correction for BMI, were correlated with pituitary volume (p = 0.001) and intensity (p = 0.049), whereas morning cortisol levels were correlated with pituitary intensity (p = 0.007). The T1-weighted pituitary intensity was negatively correlated with truncal fat (p = 0.006) and fibrinogen (p = 0.018)., Conclusions: The CHIASM study describes a quantitative reduction in pituitary intensity in T1-weighted sequences in patients with obesity. These alterations could be explained by changes in the pituitary stromal tissue, correlated with low-grade inflammation., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
17. Correction: Pituitary T1 signal intensity at magnetic resonance imaging is reduced in patients with obesity: results from the CHIASM study.
- Author
-
Puliani G, Sbardella E, Cozzolino A, Sada V, Tozzi R, Andreoli C, Fiorelli M, Di Biasi C, Corallino D, Balla A, Paganini AM, Venneri MA, Lenzi A, Lubrano C, and Isidori AM
- Published
- 2023
- Full Text
- View/download PDF
18. Platelet-derived circRNAs signature in patients with gastroenteropancreatic neuroendocrine tumors.
- Author
-
Campolo F, Sesti F, Feola T, Puliani G, Faggiano A, Tarsitano MG, Tenuta M, Hasenmajer V, Ferretti E, Verrico M, Gianfrilli D, Venneri MA, Isidori AM, and Giannetta E
- Subjects
- Male, Humans, Female, RNA, Circular genetics, Blood Platelets, Prospective Studies, RNA genetics, Neuroendocrine Tumors genetics
- Abstract
Background: Neuroendocrine tumors (NETs) early diagnosis is a clinical challenge that require a deep understanding of molecular and genetic features of this heterogeneous group of neoplasms. However, few biomarkers exist to aid diagnosis and to predict prognosis and treatment response. In the oncological field, tumor-educated platelets (TEPs) have been implicated as central players in the systemic and local responses to tumor growth, thereby altering tumor specific RNA profile. Although TEPs have been found to be enriched in RNAs, few studies have investigated the potential of a type of RNA, circular RNAs (circRNA), as platelet-derived biomarkers for cancer. In this proof-of-concept study, we aim to demonstrate whether the circRNAs signature of tumor educated platelets can be used as a liquid biopsy biomarker for the detection of gastroenteropancreatic (GEP)-NETs and the prediction of the early response to treatment., Methods: We performed a 24-months, prospective proof-of-concept study in men and women with histologically proven well-differentiated G1-G2 GEP-NET, aged 18-80 years, naïve to treatment. We performed a RNAseq analysis of circRNAs obtained from TEPs samples of 10 GEP-NETs patients at baseline and after 3 months from therapy (somatostatin analogs or surgery) and from 5 patients affected by non-malignant endocrinological diseases enrolled as a control group., Results: Statistical analysis based on p < 0.05 resulted in the identification of 252 circRNAs differentially expressed between GEP-NET and controls of which 109 were up-regulated and 143 were down-regulated in NET patients. Further analysis based on an FDR value ≤ 0.05 resulted in the selection of 5 circRNAs all highly significant downregulated. The same analysis on GEP-NETs at baseline and after therapy in 5 patients revealed an average of 4983 remarkably differentially expressed circRNAs between follow-up and baseline samples of which 2648 up-regulated and 2334 down-regulated, respectively. Applying p ≤ 0.05 and FDR ≤ 0.05 filters, only 3/5 comparisons gave statistically significant results., Conclusions: Our findings identified for the first time a circRNAs signature from TEPs as potential diagnostic and predictive biomarkers for GEP-NETs., (© 2023. BioMed Central Ltd., part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
19. Circulating Natural Killer Cells as Prognostic Value for Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Correlation with Sarcopenia.
- Author
-
Tenuta M, Pandozzi C, Sciarra F, Campolo F, Gelibter AJ, Sirgiovanni G, Cortesi E, Lenzi A, Isidori AM, Sbardella E, and Venneri MA
- Abstract
Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of tumors. Natural killer (NK) cells can play an important role in cancer immune surveillance. The aim of this prospective observational study was to analyze peripheral blood mononuclear cells (PBMCs) in patients with advanced non-small-cell lung cancer (NSCLC) receiving ICIs in order to identify predictive factors for better survival outcomes., Methods: Forty-seven stage IV NSCLC patients were enrolled. Patients underwent baseline (T
0 ) and longitudinal (T1 ) evaluations after ICIs. Peripheral immune blood cell counts were analyzed using flow cytometry., Results: Basal levels of CD3- CD56+ NK cells were higher in patients with controlled disease (DC) compared to progression disease (PD) patients (127 cells/µL vs. 27.8 cells/µL, p < 0.001). Lower NK cell values were independent prognostic factors for shorter overall survival (OS) (HR 0.992; 95% CI 0.987-0.997, p < 0.001) and progression-free survival (PFS) (HR 0.988; 95% CI 0.981-0.994, p < 0.001). During the longitudinal evaluation, CD3- CD56+ NK cells (138.1 cells/µL vs. 127 cells/µL, p = 0.025) and CD56bright NK cells (27.4 cells/µL vs. 18.1 cells/µL, p = 0.034) significantly increased in the DC group. Finally, lower values of CD3- CD56+ NK cells (28.3 cells/µL vs. 114.6 cells/µL, p = 0.004) and CD56dim NK cells (13.2 cells/µL vs. 89.4 cells/µL, p < 0.001) were found in sarcopenic patients compared to patients without sarcopenia., Conclusions: Peripheral NK cells could represent a non-invasive and useful tool to predict ICI therapy response in NSCLC patients, and the association of low NK cell levels with sarcopenia deserves even more attention in clinical evaluation.- Published
- 2023
- Full Text
- View/download PDF
20. Assessing the Impact of Polyethylene Nano/Microplastic Exposure on Human Vaginal Keratinocytes.
- Author
-
Pontecorvi P, Ceccarelli S, Cece F, Camero S, Lotti LV, Niccolai E, Nannini G, Gerini G, Anastasiadou E, Scialis ES, Romano E, Venneri MA, Amedei A, Angeloni A, Megiorni F, and Marchese C
- Subjects
- Humans, Female, Plastics, Polyethylene, Epigenesis, Genetic, Keratinocytes chemistry, Microplastics toxicity, Water Pollutants, Chemical toxicity
- Abstract
The global rise of single-use throw-away plastic products has elicited a massive increase in the nano/microplastics (N/MPLs) exposure burden in humans. Recently, it has been demonstrated that disposable period products may release N/MPLs with usage, which represents a potential threat to women's health which has not been scientifically addressed yet. By using polyethyl ene (PE) particles (200 nm to 9 μm), we showed that acute exposure to a high concentration of N/MPLs induced cell toxicity in vaginal keratinocytes after effective cellular uptake, as viability and apoptosis data suggest, along with transmission electron microscopy (TEM) observations. The internalised N/MPLs altered the expression of junctional and adherence proteins and the organisation of the actin cortex, influencing the level of genes involved in oxidative stress signalling pathways and that of miRNAs related to epithelial barrier function. When the exposure to PE N/MPLs was discontinued or became chronic, cells were able to recover from the negative effects on viability and differentiation/proliferation gene expression in a few days. However, in all cases, PE N/MPL exposure prompted a sustained alteration of DNA methyltransferase and DNA demethylase expression, which might impact epigenetic regulation processes, leading to accelerated cell ageing and inflammation, or the occurrence of malignant transformation.
- Published
- 2023
- Full Text
- View/download PDF
21. The Diagnostic Potential of the Human Blood Microbiome: Are We Dreaming or Awake?
- Author
-
Sciarra F, Franceschini E, Campolo F, and Venneri MA
- Subjects
- Humans, Wakefulness, Acute Disease, Leukocytes, Mononuclear, Liver Cirrhosis, Dysbiosis microbiology, Diabetes Mellitus, Type 2, Pancreatitis, Microbiota
- Abstract
Human blood has historically been considered a sterile environment. Recently, a thriving microbiome dominated by Firmicutes, Actinobacteria, Proteobacteria, and Bacteroidetes phyla was detected in healthy blood. The localization of these microbes is restricted to some blood cell populations, particularly the peripheral blood mononuclear cells and erythrocytes. It was hypothesized that the blood microbiome originates from the skin-oral-gut axis. In addition, many studies have evaluated the potential of blood microbiome dysbiosis as a prognostic marker in cardiovascular diseases, cirrhosis, severe liver fibrosis, severe acute pancreatitis, type 2 diabetes, and chronic kidney diseases. The present review aims to summarize current findings and most recent evidence in the field.
- Published
- 2023
- Full Text
- View/download PDF
22. Pituitary adenoma consistency affects postoperative hormone function: a retrospective study.
- Author
-
De Alcubierre D, Puliani G, Cozzolino A, Hasenmajer V, Minnetti M, Sada V, Martines V, Zaccagnino A, Ruggeri AG, Pofi R, Sbardella E, and Venneri MA
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Aged, Retrospective Studies, Prospective Studies, Postoperative Complications epidemiology, Postoperative Complications etiology, Hormones, Treatment Outcome, Pituitary Neoplasms diagnostic imaging, Pituitary Neoplasms surgery, Pituitary Neoplasms complications, Adenoma pathology
- Abstract
Background: Tumor consistency recently emerged as a key factor in surgical planning for pituitary adenomas, but its impact on postoperative endocrine function is still unclear. Our study aimed to evaluate the impact of tumor consistency on the development of postoperative pituitary deficiencies., Methods: Single-center, retrospective analysis of consecutive pituitary surgeries performed between January 2017 and January 2021 at Policlinico Umberto I in Rome. All patients underwent radiological and biochemical evaluations at baseline, and hormone assessments 3 and 6 months after pituitary surgery. Postoperative MRI studies were used to determine resection rates following surgery. Data on tumor consistency, macroscopic appearance, neurosurgical approach, and intraoperative complications were collected., Results: Fifty patients [24 women, mean age 57 ± 13 years, median tumor volume 4800 mm
3 [95% CI 620-8828], were included. Greater tumor volume (χ2 = 14.621, p = 0.006) and male sex (χ2 = 12.178, p < 0.001) were associated with worse preoperative endocrine function. All patients underwent transsphenoidal adenomectomy. Fibrous consistency was observed in 10% of patients and was associated with a Ki-67 greater than 3% (χ2 = 8.154, p = 0.04), greater risk of developing postoperative hormone deficiencies (χ2 = 4.485, p = 0.05, OR = 8.571; 95% CI: 0.876-83.908), and lower resection rates (χ2 = 8.148, p = 0.004; OR 1.385, 95% CI; 1.040-1.844). Similarly, worse resection rates were observed in tumors with suprasellar extension (χ2 = 5.048, p = 0.02; OR = 6.000, 95% CI; 1.129-31.880) and CSI (χ2 = 4.000, p = 0.04; OR = 3.857, 95% CI; 0.997-14.916)., Conclusions: Tumor consistency might provide useful information about postoperative pituitary function, likely due to its impact on surgical procedures. Further prospective studies with larger cohorts are needed to confirm our preliminary findings., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
23. Once upon a Testis: The Tale of Cyclic Nucleotide Phosphodiesterase in Testicular Cancers.
- Author
-
Campolo F, Assenza MR, Venneri MA, and Barbagallo F
- Subjects
- Male, Humans, Cyclic AMP metabolism, Phosphoric Diester Hydrolases metabolism, Cyclic GMP metabolism, Testicular Neoplasms genetics
- Abstract
Phosphodiesterases are key regulators that fine tune the intracellular levels of cyclic nucleotides, given their ability to hydrolyze cAMP and cGMP. They are critical regulators of cAMP/cGMP-mediated signaling pathways, modulating their downstream biological effects such as gene expression, cell proliferation, cell-cycle regulation but also inflammation and metabolic function. Recently, mutations in PDE genes have been identified and linked to human genetic diseases and PDEs have been demonstrated to play a potential role in predisposition to several tumors, especially in cAMP-sensitive tissues. This review summarizes the current knowledge and most relevant findings regarding the expression and regulation of PDE families in the testis focusing on PDEs role in testicular cancer development.
- Published
- 2023
- Full Text
- View/download PDF
24. Characterization of circulating immune cells and correlation with Tie2/Angiopoietins level in well differentiated neuroendocrine gastroenteropancreatic tumors: a cross-sectional analysis.
- Author
-
Sesti F, Puliani G, Feola T, Campolo F, Sciarra F, Hasenmajer V, Lenzi A, Faggiano A, Isidori AM, Venneri MA, and Giannetta E
- Subjects
- Humans, Cross-Sectional Studies, Leukocytes, Mononuclear, Pilot Projects, Tumor Microenvironment, Angiopoietins, Neuroendocrine Tumors metabolism, Receptor, TIE-2 metabolism
- Abstract
Purpose: The immune environment represents a new, but little explored, tool for understanding neuroendocrine neoplasms (NENs) behavior. An immunosuppressed microenvironment is hypothesized to promote NENs progression. A missing profiling of circulating leukocyte and peripheral blood mononuclear cells (PBMCs) subpopulations would open new perspectives in the still limited diagnostic-therapeutic management of NENs., Methods: A cross-sectional case-control pilot study was performed recruiting 30 consecutive subjects: 15 patients naïve to treatment, with histologically proven gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) and 15 healthy controls, matched for age and sex. PBMCs subpopulations were studied by flow cytometry. Soluble Tie2 (sTie2), Angiopoietin-1 (Ang-1), Angiopoietin-2 (Ang-2) were evaluated by ELISA., Results: Immune cell profiling revealed a significant lower CD3
- CD56+ natural killer (NK) cell count in NETs vs controls (p = 0.04). NK subset analysis showed a reduced relative count of CD56+ CD16+ NK cells (p =0.002) in NETs vs controls. Patients with NET showed a higher percentage of CD14+ CD16++ non-classical monocytes (p = 0.01), and a lower percentage of CD14+ CD16+ intermediate monocytes (p = 0.04). A decrease in percentage (p = 0.004) of CD4+ T-helper lymphocytes was found in NET patients. Evaluation of cellular and serum angiopoietin pathway mediators revealed in NET patients a higher relative count of Tie2-expressing monocytes (TEMs) (p < 0.001), and high levels of Ang-1 (p = 0.003) and Ang-2 (p = 0.002)., Conclusions: Patients with GEP-NET presented an immunosuppressed environment characterized by a low count of cytotoxic NK cells, a high count of anti-inflammatory non-classical monocytes, and a low count of T-helper lymphocytes. Higher levels of TEMs and angiopoietins suggest a crosstalk between innate immunity and angiogenic pathways in NETs., (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)- Published
- 2023
- Full Text
- View/download PDF
25. Gender-Specific Impact of Sex Hormones on the Immune System.
- Author
-
Sciarra F, Campolo F, Franceschini E, Carlomagno F, and Venneri MA
- Subjects
- Male, Animals, Humans, Female, Gonadal Steroid Hormones, Estrogens pharmacology, Immune System, Sex Characteristics, Androgens pharmacology, Progestins
- Abstract
Sex hormones are key determinants of gender-related differences and regulate growth and development during puberty. They also exert a broad range modulation of immune cell functions, and a dichotomy exists in the immune response between the sexes. Both clinical and animal models have demonstrated that androgens, estrogens, and progestogens mediate many of the gender-specific differences in immune responses, from the susceptibility to infectious diseases to the prevalence of autoimmune disorders. Androgens and progestogens mainly promote immunosuppressive or immunomodulatory effects, whereas estrogens enhance humoral immunity both in men and in women. This study summarizes the available evidence regarding the physiological effects of sex hormones on human immune cell function and the underlying biological mechanisms, focusing on gender differences triggered by different amounts of androgens between males and females.
- Published
- 2023
- Full Text
- View/download PDF
26. Cellular Immune Profiling of Lung and Blood Compartments in Patients with SARS-CoV-2 Infection.
- Author
-
Santinelli L, Lazzaro A, Sciarra F, Maddaloni L, Frasca F, Fracella M, Moretti S, Borsetti A, Bugani G, Alessandri F, Zullino V, Ruberto F, Pugliese F, Sorrentino L, Gianfrilli D, Isidori A, Venneri MA, Mastroianni CM, Ceccarelli G, and d'Ettorre G
- Abstract
Background: SARS-CoV-2 related immunopathology may be the driving cause underlying severe COVID-19. Through an immunophenotyping analysis on paired bronchoalveolar lavage fluid (BALF) and blood samples collected from mechanically ventilated patients with COVID-19-associated Acute Respiratory Distress Syndrome (CARDS), this study aimed to evaluate the cellular immune responses in survivors and non-survivors of COVID-19., Methods: A total of 36 paired clinical samples of bronchoalveolar lavage fluid (BALF) mononuclear cells (BALF-MC) and peripheral blood mononuclear cells (PBMC) were collected from 18 SARS-CoV-2-infected subjects admitted to the intensive care unit (ICU) of the Policlinico Umberto I, Sapienza University Hospital in Rome (Italy) for severe interstitial pneumonia. The frequencies of monocytes (total, classical, intermediate and non-classical) and Natural Killer (NK) cell subsets (total, CD56
bright and CD56dim ), as well as CD4+ and CD8+ T cell subsets [naïve, central memory (TCM) and effector memory (TEM)], and those expressing CD38 and/or HLADR were evaluated by multiparametric flow cytometry., Results: Survivors with CARDS exhibited higher frequencies of classical monocytes in blood compared to non-survivors ( p < 0.05), while no differences in the frequencies of the other monocytes, NK cell and T cell subsets were recorded between these two groups of patients ( p > 0.05). The only exception was for peripheral naïve CD4+ T cells levels that were reduced in non-survivors ( p = 0.04). An increase in the levels of CD56bright ( p = 0.012) and a decrease in CD56dim ( p = 0.002) NK cell frequencies was also observed in BALF-MC samples compared to PBMC in deceased COVID-19 patients. Total CD4+ and CD8+ T cell levels in the lung compartment were lower compared to blood ( p = 0.002 and p < 0.01, respectively) among non-survivors. Moreover, CD38 and HLA-DR were differentially expressed by CD4+ and CD8+ T cell subsets in BALF-MC and in PBMC among SARS-CoV-2-infected patients who died from COVID-19 ( p < 0.05)., Conclusions: These results show that the immune cellular profile in blood and pulmonary compartments was similar in survivors and non-survivors of COVID-19. T lymphocyte levels were reduced, but resulted highly immune-activated in the lung compartment of patients who faced a fatal outcome.- Published
- 2023
- Full Text
- View/download PDF
27. Hedgehog-GLI and Notch Pathways Sustain Chemoresistance and Invasiveness in Colorectal Cancer and Their Inhibition Restores Chemotherapy Efficacy.
- Author
-
Citarella A, Catanzaro G, Besharat ZM, Trocchianesi S, Barbagallo F, Gosti G, Leonetti M, Di Fiore A, Coppola L, Autilio TM, Spinello Z, Vacca A, De Smaele E, Venneri MA, Ferretti E, Masuelli L, and Po A
- Abstract
Colorectal cancer (CRC) is a leading cause of cancer-related mortality and chemoresistance is a major medical issue. The epithelial-to-mesenchymal transition (EMT) is the primary step in the emergence of the invasive phenotype and the Hedgehog-GLI (HH-GLI) and NOTCH signaling pathways are associated with poor prognosis and EMT in CRC. CRC cell lines harboring KRAS or BRAF mutations, grown as monolayers and organoids, were treated with the chemotherapeutic agent 5-Fluorouracil (5-FU) alone or combined with HH-GLI and NOTCH pathway inhibitors GANT61 and DAPT, or arsenic trioxide (ATO) to inhibit both pathways. Treatment with 5-FU led to the activation of HH-GLI and NOTCH pathways in both models. In KRAS mutant CRC, HH-GLI and NOTCH signaling activation co-operate to enhance chemoresistance and cell motility, while in BRAF mutant CRC, the HH-GLI pathway drives the chemoresistant and motile phenotype. We then showed that 5-FU promotes the mesenchymal and thus invasive phenotype in KRAS and BRAF mutant organoids and that chemosensitivity could be restored by targeting the HH-GLI pathway in BRAF mutant CRC or both HH-GLI and NOTCH pathways in KRAS mutant CRC. We suggest that in KRAS-driven CRC, the FDA-approved ATO acts as a chemotherapeutic sensitizer, whereas GANT61 is a promising chemotherapeutic sensitizer in BRAF-driven CRC.
- Published
- 2023
- Full Text
- View/download PDF
28. Ketogenic Diet Increases Serum and White Adipose Tissue SIRT1 Expression in Mice.
- Author
-
Tozzi R, Campolo F, Baldini E, Venneri MA, Lubrano C, Ulisse S, Gnessi L, and Mariani S
- Subjects
- Mice, Male, Animals, Sirtuin 1 genetics, Sirtuin 1 metabolism, Mice, Inbred C57BL, Obesity etiology, Obesity metabolism, Diet, High-Fat adverse effects, Adipose Tissue metabolism, Adipose Tissue, White metabolism, 3-Hydroxybutyric Acid, Diet, Ketogenic
- Abstract
Overnutrition and its sequelae have become a global concern due to the increasing incidence of obesity and insulin resistance. A ketogenic diet (KD) is widely used as a dietary treatment for metabolic disorders. Sirtuin1 (SIRT1), a metabolic sensor which regulates fat homeostasis, is modulated by dietary interventions. However, the influence of nutritional ketosis on SIRT1 is still debated. We examined the effect of KD on adipose tissue, liver, and serum levels of SIRT1 in mice. Adult C57BL/6J male mice were randomly assigned to two isocaloric dietary groups and fed with either high-fat KD or normal chow (NC) for 4 weeks. Serum SIRT1, beta-hydroxybutyrate (βHB), glucose, and triglyceride levels, as well as SIRT1 expression in visceral (VAT), subcutaneous (SAT), and brown (BAT) adipose tissues, and in the liver, were measured. KD-fed mice showed an increase in serum βHB in parallel with serum SIRT1 (r = 0.732, p = 0.0156), and increased SIRT1 protein expression in SAT and VAT. SIRT1 levels remained unchanged in BAT and in the liver, which developed steatosis. Normal glycemia and triglycerides were observed. Under a KD, serum and white fat phenotypes show higher SIRT1, suggesting that one of the molecular mechanisms underlying a KD's potential benefits on metabolic health involves a synergistic interaction with SIRT1.
- Published
- 2022
- Full Text
- View/download PDF
29. The NO/cGMP/PKG pathway in platelets: The therapeutic potential of PDE5 inhibitors in platelet disorders.
- Author
-
Degjoni A, Campolo F, Stefanini L, and Venneri MA
- Subjects
- Humans, Male, Blood Platelets metabolism, Cyclic GMP metabolism, Cyclic GMP-Dependent Protein Kinases metabolism, Cyclic Nucleotide Phosphodiesterases, Type 5 metabolism, Cyclic Nucleotide Phosphodiesterases, Type 5 pharmacology, Guanosine metabolism, Guanosine pharmacology, Guanylate Cyclase metabolism, Guanylate Cyclase pharmacology, Nitric Oxide Donors metabolism, Nucleotides, Cyclic metabolism, Nucleotides, Cyclic pharmacology, Platelet Aggregation Inhibitors pharmacology, Platelet Aggregation Inhibitors therapeutic use, Protein Kinases metabolism, Nitric Oxide metabolism, Phosphodiesterase 5 Inhibitors pharmacology, Phosphodiesterase 5 Inhibitors therapeutic use, Phosphodiesterase 5 Inhibitors metabolism
- Abstract
Platelets are the "guardians" of the blood circulatory system. At sites of vessel injury, they ensure hemostasis and promote immunity and vessel repair. However, their uncontrolled activation is one of the main drivers of thrombosis. To keep circulating platelets in a quiescent state, the endothelium releases platelet antagonists including nitric oxide (NO) that acts by stimulating the intracellular receptor guanylyl cyclase (GC). The latter produces the second messenger cyclic guanosine-3',5'-monophosphate (cGMP) that inhibits platelet activation by stimulating protein kinase G, which phosphorylates hundreds of intracellular targets. Intracellular cGMP pools are tightly regulated by a fine balance between GC and phosphodiesterases (PDEs) that are responsible for the hydrolysis of cyclic nucleotides. Phosphodiesterase type 5 (PDE5) is a cGMP-specific PDE, broadly expressed in most tissues in humans and rodents. In clinical practice, PDE5 inhibitors (PDE5i) are used as first-line therapy for erectile dysfunction, pulmonary artery hypertension, and lower urinary tract symptoms. However, several studies have shown that PDE5i may ameliorate the outcome of various other conditions, like heart failure and stroke. Interestingly, NO donors and cGMP analogs increase the capacity of anti-platelet drugs targeting the purinergic receptor type Y, subtype 12 (P2Y12) receptor to block platelet aggregation, and preclinical studies have shown that PDE5i inhibits platelet functions. This review summarizes the molecular mechanisms underlying the effect of PDE5i on platelet activation and aggregation focusing on the therapeutic potential of PDE5i in platelet disorders, and the outcomes of a combined therapy with PDE5i and NO donors to inhibit platelet activation., (© 2022 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis.)
- Published
- 2022
- Full Text
- View/download PDF
30. Revisiting the physiological role of androgens in women.
- Author
-
Rosato E, Sciarra F, Anastasiadou E, Lenzi A, and Venneri MA
- Subjects
- Pregnancy, Female, Humans, Menopause, Menstrual Cycle, Androgens, Dehydroepiandrosterone
- Abstract
Introduction: Extensive research underlines the critical functions of androgens in females. Nevertheless, the precise mechanisms of their action are poorly understood. Here, we review the existing literature regarding the physiological role of androgens in women throughout life., Areas Covered: Several studies show that androgen receptors (ARs) are broadly expressed in numerous female tissues. They are essential for many physiological processes, including reproductive, sexual, cardiovascular, bone, muscle, and brain health. They are also involved in adipose tissue and liver function. Androgen levels change with the menstrual cycle and decrease in the first decades of life, independently of menopause., Expert Opinion: To date, studies are limited by including small numbers of women, the difficulty of dosing androgens, and their cyclical variations. In particular, whether androgens play any significant role in regulating the establishment of pregnancy is poorly understood. The neural functions of ARs have also been investigated less thoroughly, although it is expressed at high levels in brain structures. Moreover, the mechanism underlying the decline of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) with age is unclear. Other factors, including estrogen's effect on adrenal androgen production, reciprocal regulation of ARs, and non-classical effects of androgens, remain to be determined.
- Published
- 2022
- Full Text
- View/download PDF
31. cAMP-specific phosphodiesterase 8A and 8B isoforms are differentially expressed in human testis and Leydig cell tumor.
- Author
-
Campolo F, Capponi C, Tarsitano MG, Tenuta M, Pozza C, Gianfrilli D, Magliocca F, Venneri MA, Vicini E, Lenzi A, Isidori AM, and Barbagallo F
- Subjects
- Humans, Male, Adenosine Monophosphate, Protein Isoforms, Semen, 3',5'-Cyclic-AMP Phosphodiesterases genetics, 3',5'-Cyclic-AMP Phosphodiesterases metabolism, Leydig Cell Tumor genetics
- Abstract
Cyclic adenosine monophosphate/Protein kinase A (cAMP/PKA) signaling pathway is the master regulator of endocrine tissue function. The level, compartmentalization and amplitude of cAMP response are finely regulated by phosphodiesterases (PDEs). PDE8 is responsible of cAMP hydrolysis and its expression has been characterized in all steroidogenic cell types in rodents including adrenal and Leydig cells in rodents however scarce data are currently available in humans. Here we demonstrate that human Leydig cells express both PDE8A and PDE8B isoforms. Interestingly, we found that the expression of PDE8B but not of PDE8A is increased in transformed Leydig cells (Leydig cell tumors-LCTs) compared to non-tumoral cells. Immunofluorescence analyses further reveals that PDE8A is also highly expressed in specific spermatogenic stages. While the protein is not detected in spermatogonia it accumulates nearby the forming acrosome, in the trans-Golgi apparatus of spermatocytes and spermatids and it follows the fate of this organelle in the later stages translocating to the caudal part of the cell. Taken together our findings suggest that 1) a specific pool(s) of cAMP is/are regulated by PDE8A during spermiogenesis pointing out a possible new role of this PDE8 isoform in key events governing the differentiation and maturation of human sperm and 2) PDE8B can be involved in Leydig cell transformation., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Campolo, Capponi, Tarsitano, Tenuta, Pozza, Gianfrilli, Magliocca, Venneri, Vicini, Lenzi, Isidori and Barbagallo.)
- Published
- 2022
- Full Text
- View/download PDF
32. The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males.
- Author
-
Croci S, Venneri MA, Mantovani S, Fallerini C, Benetti E, Picchiotti N, Campolo F, Imperatore F, Palmieri M, Daga S, Gabbi C, Montagnani F, Beligni G, Farias TDJ, Carriero ML, Di Sarno L, Alaverdian D, Aslaksen S, Cubellis MV, Spiga O, Baldassarri M, Fava F, Norman PJ, Frullanti E, Isidori AM, Amoroso A, Mari F, Furini S, Mondelli MU, Gen-Covid Multicenter Study, Chiariello M, Renieri A, and Meloni I
- Subjects
- Autophagy genetics, Biomarkers, HEK293 Cells, Humans, Hydroxychloroquine therapeutic use, Male, Polymorphism, Single Nucleotide, SARS-CoV-2 genetics, Severity of Illness Index, COVID-19 genetics, Toll-Like Receptor 3 genetics
- Abstract
The polymorphism L412F in TLR3 has been associated with several infectious diseases. However, the mechanism underlying this association is still unexplored. Here, we show that the L412F polymorphism in TLR3 is a marker of severity in COVID-19. This association increases in the sub-cohort of males. Impaired macroautophagy/autophagy and reduced TNF/TNFα production was demonstrated in HEK293 cells transfected with TLR3
L412F -encoding plasmid and stimulated with specific agonist poly(I:C). A statistically significant reduced survival at 28 days was shown in L412F COVID-19 patients treated with the autophagy-inhibitor hydroxychloroquine (p = 0.038). An increased frequency of autoimmune disorders such as co-morbidity was found in L412F COVID-19 males with specific class II HLA haplotypes prone to autoantigen presentation. Our analyses indicate that L412F polymorphism makes males at risk of severe COVID-19 and provides a rationale for reinterpreting clinical trials considering autophagy pathways. Abbreviations: AP: autophagosome; AUC: area under the curve; BafA1: bafilomycin A1; COVID-19: coronavirus disease-2019; HCQ: hydroxychloroquine; RAP: rapamycin; ROC: receiver operating characteristic; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; TLR: toll like receptor; TNF/TNF-α: tumor necrosis factor.- Published
- 2022
- Full Text
- View/download PDF
33. Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial.
- Author
-
Pofi R, Giannetta E, Feola T, Galea N, Barbagallo F, Campolo F, Badagliacca R, Barbano B, Ciolina F, Defeudis G, Filardi T, Sesti F, Minnetti M, Vizza CD, Pasqualetti P, Caboni P, Carbone I, Francone M, Catalano C, Pozzilli P, Lenzi A, Venneri MA, Gianfrilli D, and Isidori AM
- Subjects
- Carbolines pharmacology, Carbolines therapeutic use, Cyclic Nucleotide Phosphodiesterases, Type 5, Double-Blind Method, Female, Humans, Kinetics, Male, Penile Erection, Phosphodiesterase 5 Inhibitors pharmacology, Phosphodiesterase 5 Inhibitors therapeutic use, Tadalafil pharmacology, Tadalafil therapeutic use, Treatment Outcome, Ventricular Remodeling, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 drug therapy, Erectile Dysfunction drug therapy, Erectile Dysfunction etiology, MicroRNAs
- Abstract
Cyclic GMP-phosphodiesterase type 5 (PDE5) inhibition has been shown to counteract maladaptive cardiac changes triggered by diabetes in some but not all studies. We performed a single-center, 20-week, double-blind, randomized, placebo-controlled trial (NCT01803828) to assess sex differences in cardiac remodeling after PDE5 inhibition in patients with diabetic cardiomyopathy. A total of 122 men and women (45 to 80 years) with long-duration (>3 years) and well-controlled type 2 diabetes mellitus (T2DM; HbA1c < 86 mmol/mol) were selected according to echocardiographic signs of cardiac remodeling. Patients were randomly assigned (1:1) to placebo or oral tadalafil (20 mg, once daily). The primary outcome was to evaluate sex differences in cardiac torsion change. Secondary outcomes were changes in cardiovascular, metabolic, immune, and renal function. At 20 weeks, the treatment-by-sex interaction documented an improvement in cardiac torsion (-3.40°, -5.96; -0.84, P = 0.011) and fiber shortening (-1.19%, -2.24; -0.14, P = 0.027) in men but not women. The primary outcome could not be explained by differences in cGMP concentrations or tadalafil pharmacodynamics. In both sexes, tadalafil improved hsa-miR-199-5p expression, biomarkers of cardiovascular remodeling, albuminuria, renal artery resistive index, and circulating Klotho concentrations. Immune cell profiling revealed an improvement in low-grade chronic inflammation: Classic CD14
++ CD16- monocytes reduced, and Tie2+ monocytes increased. Nine patients (14.5%) had minor adverse reactions after tadalafil administration. Continuous PDE5 inhibition could offer a strategy to target cardiorenal complications of T2DM, with sex- and tissue-specific responses. Further studies are needed to confirm Klotho and hsa-miR-199-5p as markers for T2DM complications.- Published
- 2022
- Full Text
- View/download PDF
34. Human genital tracts microbiota: dysbiosis crucial for infertility.
- Author
-
Venneri MA, Franceschini E, Sciarra F, Rosato E, D'Ettorre G, and Lenzi A
- Subjects
- Dysbiosis microbiology, Female, Humans, Infant, Newborn, Male, Placenta, Pregnancy, Vagina, Infertility etiology, Microbiota
- Abstract
Human body is colonized by trillions of microbes, influenced by several factors, both endogenous, as hormones and circadian regulation, and exogenous as, life-style habits and nutrition. The alteration of such factors can lead to microbial dysbiosis, a phenomenon which, in turn, represents a risk factor in many different pathologies including cancer, diabetes, autoimmune and cardiovascular disease, and infertility. Female microbiota dysbiosis (vaginal, endometrial, placental) and male microbiota dysbiosis (seminal fluid) can influence the fertility, determining a detrimental impact on various conditions, as pre-term birth, neonatal illnesses, and macroscopic sperm parameters impairments. Furthermore, unprotected sexual intercourse creates a bacterial exchange between partners, and, in addition, each partner can influence the microbiota composition of partner's reproductive tracts. This comprehensive overview of the effects of bacterial dysbiosis in both sexes and how partners might influence each other will allow for better personalization of infertility management., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
35. Angiogenic factors as prognostic markers in neuroendocrine neoplasms.
- Author
-
Puliani G, Sesti F, Anastasi E, Verrico M, Tarsitano MG, Feola T, Campolo F, Di Gioia CRT, Venneri MA, Angeloni A, Appetecchia M, Lenzi A, Isidori AM, Faggiano A, and Giannetta E
- Subjects
- Angiogenesis Inducing Agents, Humans, Prognosis, Intestinal Neoplasms pathology, Neuroendocrine Tumors pathology, Pancreatic Neoplasms pathology, Stomach Neoplasms pathology
- Abstract
Purpose: Angiogenic markers in neuroendocrine neoplasms (NENs) have recently received increasing attention, but their clinical role remains unclear. The aim of this study was to evaluate the role of angiogenic markers in NEN aggressiveness and prognosis., Methods: We performed a prospective observational study including 46 consecutive patients with proven NENs of pulmonary (45.65%) and gastro-entero-pancreatic (GEP) (54.35%) origin and 29 healthy controls. Circulating pro-angiogenic factors were measured by ELISA assay. ANG2 tissue expression was evaluated in a subgroup of ten patients by immunohistochemistry., Results: The study demonstrated a significantly higher level of ANG2, ANG1, sTIE2, and PROK2 in patients affected by NENs compared to controls. In the NENs' group we measured that: (i) ANG2 levels were higher in poorly vs well-differentiated NENs: 4.85 (2.75-7.42) vs 3.16 (1.66-6.36) ng/ml, p = 0.046 and in tumor stage 3-4 compared to stage 1-2: 4.24 (2.66-8.72) vs 2.73 (1.53-5.70), p = 0.044; (ii) ANG2 and PROK2 were significantly higher in patents with progressive disease compared to stable disease: ANG2 = 6.26 (3.98-10.99) vs 2.73 (1.65-4.36) pg/ml, p = 0.001; PROK2 = 29.19 (28.42-32.25) vs 28.37 (28.14-28.91) pg/ml, p = 0.035. Immunohistochemistry confirmed ANG2 expression in tumor specimens., Conclusions: We documented higher levels of angiogenic markers in NENs, with an association between ANG2 serum levels and NENs morphology and staging. In both GEP and lung NENs, ANG2 and PROK2 are higher in case of tumor progression, suggesting a potential role as prognostic markers in NENs patients., (© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
36. MicroRNA loaded edible nanoparticles: an emerging personalized therapeutic approach for the treatment of obesity and metabolic disorders.
- Author
-
Campolo F, Catanzaro G, Venneri MA, Ferretti E, and Besharat ZM
- Subjects
- Epigenesis, Genetic, Humans, Obesity metabolism, Metabolic Diseases genetics, Metabolic Diseases therapy, MicroRNAs genetics, MicroRNAs metabolism, Nanoparticles
- Abstract
Obesity is a metabolic chronic disease whose prevalence is strongly growing in the last years, reaching pandemic proportions. Nowadays weight loss, achieved through lifestyle changes, is the first line therapeutic objective, although great inter-individual variabilities influence response to treatment, suggesting the involvement of epigenetic factors. In this contest, there is increasing recognition of the role of small RNA molecules, particularly microRNAs in the epigenetic regulation of genes involved in adipose tissue and glucose metabolism and several microRNAs have been found to be dysregulated in obesity and metabolic diseases. The development of novel personalized therapeutic strategies using microRNAs bears promise. However, the application of naked microRNAs has been hampered by their low specificity and sensitivity. In a recent issue of Theranostics , Kumar et al. explored the possibility of microRNA delivery through ginger-derived nanoparticles (GDNPs) as an alternative therapeutic approach for obesity treatment. The results reported by Kumar et al., addressing non-coding RNAs and edible plant derived nanoparticles, open new perspectives for the application of this innovative and safe delivery system in the clinical practice for the treatment of obesity and other metabolic disorders., Competing Interests: Competing Interests: The authors have declared that no competing interest exists., (© The author(s).)
- Published
- 2022
- Full Text
- View/download PDF
37. Impact of Sarcopenia and Inflammation on Patients with Advanced Non-Small Cell Lung Cancer (NCSCL) Treated with Immune Checkpoint Inhibitors (ICIs): A Prospective Study.
- Author
-
Tenuta M, Gelibter A, Pandozzi C, Sirgiovanni G, Campolo F, Venneri MA, Caponnetto S, Cortesi E, Marchetti P, Isidori AM, and Sbardella E
- Abstract
Background: Sarcopenia is a condition characterized by loss of skeletal muscle mass associated with worse clinical outcomes in cancer patients. Data on sarcopenia in patients undergoing immune checkpoint inhibitors (ICI) therapy are still limited. The aim of this prospective observational study was to investigate the relationship between sarcopenia, ICI treatment response and immunological profile, in patients with advanced non-small cell lung cancer (NSCLC)., Methods: Forty-seven stage IV NSCLC patient candidates for starting ICI, were enrolled from the Policlinico Umberto I outpatient Oncology. Patients underwent baseline blood test, inflammatory markers, cytokine assessment and body composition with dual-energy X-ray absorptiometry (DXA). Sarcopenia was defined with appendicular skeletal muscle mass over height
2 (ASM/heigh2 )., Results: Overall, 19/47 patients (40.4%) results were sarcopenic. Sarcopenic patients showed significantly shorter PFS than non-sarcopenic ones (20.3 weeks, 95% CI 7.5-33.1 vs. 61 weeks, 95% CI 22.5-99.4, p = 0.047). Specifically, they had an 8.1 times higher risk of progression disease (PD) than non-sarcopenic patients (OR 8.1, 95%, p = 0.011)., Conclusions: Sarcopenic patients showed worse PFS and had a higher risk of PD compared to non-sarcopenic ones. Therefore, sarcopenia may reflect the increased metabolic activity of more aggressive tumors, which involves systemic inflammation and muscle wasting and could be considered a negative predictive factor for ICI response.- Published
- 2021
- Full Text
- View/download PDF
38. Priming metabolism with the type 5 phosphodiesterase: the role of cGMP-hydrolyzing enzymes.
- Author
-
Campolo F, Pofi R, Venneri MA, and Isidori AM
- Subjects
- Cyclic Nucleotide Phosphodiesterases, Type 5 metabolism, Humans, Cyclic GMP, Signal Transduction
- Abstract
The cyclic guanosine monophosphate (cGMP) signaling system is one of the most prominent regulators of many physiopathological processes in humans and rodents. It has been strongly established as an accomplished cellular signal involved in the regulation of energy homeostasis and cell metabolism, and pharmacological enhancement of cGMP has shown beneficial effects in metabolic disorders models. cGMP intracellular levels are finely regulated by phosphodiesterases (PDEs). The main enzyme responsible for the degradation of cGMP is PDE5. Preclinical and clinical studies have shown that PDE5 inhibitors (PDE5i) have beneficial effects on improving insulin resistance and glucose metabolism representing a promising therapeutic strategy for the treatment of metabolic disorders. This review aims to describe the molecular basis underlying the use of PDE5i to prompt cell metabolism and summarize current clinical trials assessing the effects of PDE5i on glucose metabolism., (Copyright © 2021. Published by Elsevier Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
39. Calcineurin Gamma Catalytic Subunit PPP3CC Inhibition by miR-200c-3p Affects Apoptosis in Epithelial Ovarian Cancer.
- Author
-
Anastasiadou E, Messina E, Sanavia T, Labruna V, Ceccarelli S, Megiorni F, Gerini G, Pontecorvi P, Camero S, Perniola G, Venneri MA, Trivedi P, Lenzi A, and Marchese C
- Subjects
- Biopsy, Carcinoma, Ovarian Epithelial genetics, Case-Control Studies, Cell Movement genetics, Cell Proliferation genetics, Female, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Humans, Ovarian Neoplasms genetics, RNA Interference physiology, Tumor Cells, Cultured, Apoptosis genetics, Calcineurin genetics, Carcinoma, Ovarian Epithelial pathology, MicroRNAs physiology, Ovarian Neoplasms pathology
- Abstract
Epithelial ovarian cancer (EOC) outpaces all the other forms of the female reproductive system malignancies. MicroRNAs have emerged as promising predictive biomarkers to therapeutic treatments as their expression might characterize the tumor stage or grade. In EOC, miR-200c is considered a master regulator of oncogenes or tumor suppressors. To investigate novel miR-200c-3p target genes involved in EOC tumorigenesis, we evaluated the association between this miRNA and the mRNA expression of several potential target genes by RNA-seq data of both 46 EOC cell lines from Cancer Cell line Encyclopedia (CCLE) and 456 EOC patient bio-specimens from The Cancer Genome Atlas (TCGA). Both analyses showed a significant anticorrelation between miR-200c-3p and the protein phosphatase 3 catalytic subunit γ of calcineurin (PPP3CC) levels involved in the apoptosis pathway. Quantitative mRNA expression analysis in patient biopsies confirmed the inverse correlation between miR-200c-3p and PPP3CC levels. In vitro regulation of PPP3CC expression through miR-200c-3p and RNA interference technology led to a concomitant modulation of BCL2- and p-AKT-related pathways, suggesting the tumor suppressive role of PPP3CC in EOC. Our results suggest that inhibition of high expression of miR-200c-3p in EOC might lead to overexpression of the tumor suppressor PPP3CC and subsequent induction of apoptosis in EOC patients.
- Published
- 2021
- Full Text
- View/download PDF
40. From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?
- Author
-
Vitale G, Dicitore A, Barrea L, Sbardella E, Razzore P, Campione S, Faggiano A, Colao A, Albertelli M, Altieri B, Bottiglieri F, De Cicco F, Di Molfetta S, Fanciulli G, Feola T, Ferone D, Ferraù F, Gallo M, Giannetta E, Grillo F, Grossrubatscher E, Guadagno E, Guarnotta V, Isidori AM, Lania A, Lenzi A, Calzo FL, Malandrino P, Messina E, Modica R, Muscogiuri G, Pes L, Pizza G, Pofi R, Puliani G, Rainone C, Rizza L, Rubino M, Ruggieri RM, Sesti F, Venneri MA, and Zatelli MC
- Subjects
- Dysbiosis, Humans, Gastrointestinal Microbiome, Gastrointestinal Neoplasms, Microbiota, Neuroendocrine Tumors
- Abstract
Gut microbiota is represented by different microorganisms that colonize the intestinal tract, mostly the large intestine, such as bacteria, fungi, archaea and viruses. The gut microbial balance has a key role in several functions. It modulates the host's metabolism, maintains the gut barrier integrity, participates in the xenobiotics and drug metabolism, and acts as protection against gastro-intestinal pathogens through the host's immune system modulation. The impaired gut microbiota, called dysbiosis, may be the result of an imbalance in this equilibrium and is linked with different diseases, including cancer. While most of the studies have focused on the association between microbiota and gastrointestinal adenocarcinomas, very little is known about gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs). In this review, we provide an overview concerning the complex interplay between gut microbiota and GEP NENs, focusing on the potential role in tumorigenesis and progression in these tumors., (© 2020. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
41. Diabetic Cardiomiopathy Progression is Triggered by miR122-5p and Involves Extracellular Matrix: A 5-Year Prospective Study.
- Author
-
Pofi R, Giannetta E, Galea N, Francone M, Campolo F, Barbagallo F, Gianfrilli D, Venneri MA, Filardi T, Cristini C, Antonini G, Badagliacca R, Frati G, Lenzi A, Carbone I, and Isidori AM
- Subjects
- Animals, Extracellular Matrix, Humans, Longitudinal Studies, Mice, Predictive Value of Tests, Prospective Studies, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 genetics, MicroRNAs
- Abstract
Objectives: The purpose of this study was to follow the long-term progression of diabetic cardiomyopathy by combining cardiac magnetic resonance (CMR) and molecular analysis., Background: The evolution of diabetic cardiomyopathy to heart failure affects patients'morbidity and mortality. CMR is the gold standard to assess cardiac remodeling, but there is a lack of markers linked to the mechanism of diabetic cardiomyopathy progression., Methods: Five-year longitudinal study on patients with type 2 diabetes mellitus (T2DM) enrolled in the CECSID (Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes) trial compared with nondiabetic age-matched controls. CMR with tagging together with metabolic and molecular assessments were performed at baseline and 5-year follow-up., Results: A total of 79 men (age 64 ± 8 years) enrolled, comprising 59 men with T2DM compared with 20 nondiabetic age-matched controls. Longitudinal CMR with tagging showed an increase in ventricular mass (ΔLVMi = 13.47 ± 29.66 g/m
2 ; p = 0.014) and a borderline increase in end-diastolic volume (ΔEDVi = 5.16 ± 14.71 ml/m2 ; p = 0.056) in men with T2DM. Cardiac strain worsened (Δσ = 1.52 ± 3.85%; p = 0.033) whereas torsion was unchanged (Δθ = 0.24 ± 4.04°; p = 0.737), revealing a loss of the adaptive equilibrium between strain and torsion. Contraction dynamics showed a decrease in the systolic time-to-peak (ΔTtP = -35.18 ± 28.81 ms; p < 0.001) and diastolic early recoil-rate (ΔRR = -20.01 ± 19.07 s-1 ; p < 0.001). The ejection fraction and metabolic parameters were unchanged. Circulating miR microarray revealed an up-regulation of miR122-5p. Network analysis predicted the matrix metalloproteinases (MMPs) MMP-16 and MMP-2 and their regulator (tissue inhibitors of metalloproteinases) as targets. In db/db mice we demonstrated that miR122-5p expression is associated with diabetic cardiomyopathy, that in the diabetic heart is overexpressed, and that, in vitro, it regulates MMP-2. Finally, we demonstrated that miR122-5p overexpression affects the extracellular matrix through MMP-2 modulation., Conclusions: Within 5 years of diabetic cardiomyopathy onset, increasing cardiac hypertrophy is associated with progressive impairment in strain, depletion of the compensatory role of torsion, and changes in viscoelastic contraction dynamics. These changes are independent of glycemic control and paralleled by the up-regulation of specific microRNAs targeting the extracellular matrix. (Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes [CECSID]; NCT00692237)., Competing Interests: Funding Support And Author Disclosures The work was funded by the Italian Ministry of University and Research MIUR - PRIN 2015ZTT5KB. Dr. Isidori has received consultation fees, unconditional grants, and hospitality to conferences from IBSA, Takeda, and IPSEN. Dr. Filardi received hospitality to conferences from Sanofi and Merck. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
42. Impaired Immune Function in Patients With Chronic Postsurgical Hypoparathyroidism: Results of the EMPATHY Study.
- Author
-
Puliani G, Hasenmajer V, Sciarra F, Barbagallo F, Sbardella E, Pofi R, Gianfrilli D, Romagnoli E, Venneri MA, and Isidori AM
- Subjects
- Adult, Aged, Autoimmunity physiology, CD4-Positive T-Lymphocytes pathology, Calcium blood, Case-Control Studies, Chronic Disease, Cross-Sectional Studies, Female, Humans, Hypoparathyroidism blood, Hypoparathyroidism etiology, Immune System physiology, Immune System Diseases blood, Immune System Diseases immunology, Italy, Leukocytes, Mononuclear pathology, Male, Middle Aged, Parathyroid Hormone blood, Parathyroidectomy adverse effects, Pilot Projects, Postoperative Complications blood, Postoperative Complications etiology, Receptor, Parathyroid Hormone, Type 1 blood, Hypoparathyroidism immunology, Immune System Diseases etiology, Postoperative Complications immunology
- Abstract
Context: Despite the pivotal role of calcium signaling in immune response, little is known about immune function in patients affected by hypoparathyroidism., Objective: This work aimed to evaluate immune function in hypoparathyroidism., Methods: The Evaluation of iMmune function in Postsurgical and AuToimmune HYpoparathyroidism (NCT04059380) is a case-control, cross-sectional study set in an Italian referral center. Participants included 20 patients with postsurgical hypoparathyroidism (12 females) and 20 age- and sex-matched controls. Main outcome measures included calcium metabolism assessment, peripheral blood mononuclear cells (PBMC) profiling via flow cytometry, parathyroid hormone receptor 1 (PTHr1) expression analysis using immunofluorescence and PrimeFlow RNA assay, gene expression analysis via real-time polymerase chain reaction, cytokine measurement, and evaluation of infectious disease frequency and severity., Results: Immune cell profiling revealed decreased monocytes, regulatory, naive, and total CD4+ T lymphocytes, which correlated with total calcium, ionized calcium, and PTH levels, in patients with hypoparathyroidism. Patients with hypoparathyroidism had a higher CD3-CD56+ natural killer (NK) cell count, which inversely correlated with calcium, PTH, and vitamin D levels. Furthermore, they exhibited decreased tumor necrosis factor (TNF) and granulocyte-macrophage colony-stimulating factor gene expression and decreased circulating TNF levels. Gene expression and immunofluorescence analysis confirmed PTHr1 expression in all PBMC lineages; however, the percentage of cells expressing PTHr1 was lower, whereas the intensity of PTHr1 expression in monocytes, total T lymphocytes, CD8+CD4+ and CD4+ T lymphocytes, and total NK cells was higher in patients with hypoparathyroidism., Conclusions: This study describes for the first time the immune alterations in patients with hypoparathyroidism receiving conventional therapies, supporting the immunoregulatory role of PTH and proposing an explanation for the increased susceptibility to infections observed in epidemiological studies., (© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
43. Novel Nanoarchitectures Based on Lignin Nanoparticles for Electrochemical Eco-Friendly Biosensing Development.
- Author
-
Tortolini C, Capecchi E, Tasca F, Pofi R, Venneri MA, Saladino R, and Antiochia R
- Abstract
Novel nanoarchitectures based on lignin nanoparticles (LNPs) were designed and realized for electrochemical eco-friendly biosensing development. Two types of lignin nanoparticles were utilized for the modification of a gold bare electrode, namely organosolv (OLNPs) and kraft lignin (KLNPs) nanoparticles, synthetized from a sulfur-free and a sulfur lignin, respectively. The electrochemical behavior of LNP-modified electrodes was studied using two electrochemical techniques, cyclic voltammetry (CV) and electrochemical impedance spectroscopy (EIS). Compared to the gold bare electrode, an evident decrease in the faradaic current and increase of the ΔE
p were observed in cyclic voltammograms. In addition, larger semicircles were registered in Nyquist plots. These results suggest a strong inhibition effect of the electron transfer reaction by LNPs layer, especially in the case of KLNPs. The modified electrodes, properly assembled with concanavalin A (ConA) and glucose oxidase (GOx), were successively tested as biosensing platforms for glucose, showing a sensitivity of (4.53 ± 0.467) and (13.74 ± 1.84) μA mM-1 cm2 for Au/SAMCys/OLNPs/ConA/GOx and Au/KLNPs/ConA/GOx biosensors, respectively. Finally, different layers of the KNLPs/ConA/GOx-modified Au electrode were tested, and the three-layered Au(KNLPs/ConA/GOx)3 showed the best analytical performance.- Published
- 2021
- Full Text
- View/download PDF
44. Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males.
- Author
-
Baldassarri M, Picchiotti N, Fava F, Fallerini C, Benetti E, Daga S, Valentino F, Doddato G, Furini S, Giliberti A, Tita R, Amitrano S, Bruttini M, Croci S, Meloni I, Pinto AM, Iuso N, Gabbi C, Sciarra F, Venneri MA, Gori M, Sanarico M, Crawley FP, Pagotto U, Fanelli F, Mezzullo M, Dominguez-Garrido E, Planas-Serra L, Schlüter A, Colobran R, Soler-Palacin P, Lapunzina P, Tenorio J, Pujol A, Castagna MG, Marcelli M, Isidori AM, Renieri A, Frullanti E, and Mari F
- Subjects
- Aged, Case-Control Studies, Critical Care statistics & numerical data, Female, Genome, Human genetics, Humans, Male, Middle Aged, Polymorphism, Single Nucleotide genetics, Risk Factors, SARS-CoV-2, Severity of Illness Index, Spain, Testosterone blood, COVID-19 pathology, Peptides genetics, Receptors, Androgen genetics
- Abstract
Background: While SARS-CoV-2 similarly infects men and women, COVID-19 outcome is less favorable in men. Variability in COVID-19 severity may be explained by differences in the host genome., Methods: We compared poly-amino acids variability from WES data in severely affected COVID-19 patients versus SARS-CoV-2 PCR-positive oligo-asymptomatic subjects., Findings: Shorter polyQ alleles (≤22) in the androgen receptor (AR) conferred protection against severe outcome in COVID-19 in the first tested cohort (both males and females) of 638 Italian subjects. The association between long polyQ alleles (≥23) and severe clinical outcome (p = 0.024) was also validated in an independent cohort of Spanish men <60 years of age (p = 0.014). Testosterone was higher in subjects with AR long-polyQ, possibly indicating receptor resistance (p = 0.042 Mann-Whitney U test). Inappropriately low serum testosterone level among carriers of the long-polyQ alleles (p = 0.0004 Mann-Whitney U test) predicted the need for intensive care in COVID-19 infected men. In agreement with the known anti-inflammatory action of testosterone, patients with long-polyQ and age ≥60 years had increased levels of CRP (p = 0.018, not accounting for multiple testing)., Interpretation: We identify the first genetic polymorphism that appears to predispose some men to develop more severe disease. Failure of the endocrine feedback to overcome AR signaling defects by increasing testosterone levels during the infection leads to the polyQ tract becoming dominant to serum testosterone levels for the clinical outcome. These results may contribute to designing reliable clinical and public health measures and provide a rationale to test testosterone as adjuvant therapy in men with COVID-19 expressing long AR polyQ repeats., Funding: MIUR project "Dipartimenti di Eccellenza 2018-2020" to Department of Medical Biotechnologies University of Siena, Italy (Italian D.L. n.18 March 17, 2020) and "Bando Ricerca COVID-19 Toscana" project to Azienda Ospedaliero-Universitaria Senese. Private donors for COVID-19 research and charity funds from Intesa San Paolo., Competing Interests: Declaration of Competing Interest The authors declare no competing interests., (Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
45. Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection. The DEDALO project.
- Author
-
Isidori AM, Giannetta E, Pofi R, Venneri MA, Gianfrilli D, Campolo F, Mastroianni CM, Lenzi A, and d'Ettorre G
- Subjects
- Antiviral Agents adverse effects, COVID-19 enzymology, COVID-19 virology, Clinical Trials as Topic, Host-Pathogen Interactions, Humans, Molecular Targeted Therapy, Nitric Oxide adverse effects, Nitric Oxide metabolism, Phosphodiesterase 5 Inhibitors adverse effects, SARS-CoV-2 pathogenicity, Signal Transduction, Treatment Outcome, Antiviral Agents therapeutic use, Cyclic GMP metabolism, Cyclic Nucleotide Phosphodiesterases, Type 5 metabolism, Nitric Oxide therapeutic use, Phosphodiesterase 5 Inhibitors therapeutic use, SARS-CoV-2 drug effects, COVID-19 Drug Treatment
- Abstract
Background: A pandemic outbreak of COVID-19 has been sweeping the world since December. It begins as a respiratory infection that, mainly in men with diabetes or renal impairment, evolves into a systemic disease, with SARDS, progressive endothelial cell damage, abnormal clotting and impaired cardiovascular and liver function. Some clinical trials are testing biological drugs to limit the immune system dysregulation, "cytokines storm," that causes the systemic complications of COVID-19. The contraindications of these drugs and their cost raise concerns over the implications of their widespread availability., Objectives: Numerous clinical and experimental studies have revealed a role for the nitric oxide (NO)-cyclic GMP-phosphodiesterase type 5 (PDE5) pathway in modulating low-grade inflammation in patients with metabolic diseases, offering cardiovascular protection. PDE5 inhibition favors an anti-inflammatory response by modulating activated T cells, reducing cytokine release, lowering fibrosis, increasing oxygen diffusion, stimulating vascular repair. PDE5 is highly expressed in the lungs, where its inhibition improves pulmonary fibrosis, a complication of severe COVID-19 disease., Materials and Methods: We performed a systematic review of all evidence documenting any involvement of the NO-cGMP-PDE5 axis in the pathophysiology of COVID-19, presenting the ongoing clinical trials aimed at modulating this axis, including our own "silDEnafil administration in DiAbetic and dysmetaboLic patients with COVID-19 (DEDALO trial).", Results: The reviewed evidence suggests that PDE5 inhibitors could offer a new strategy in managing COVID-19 by (i) counteracting the Ang-II-mediated downregulation of AT-1 receptor; (ii) acting on monocyte switching, thus reducing pro-inflammatory cytokines, interstitial infiltration and the vessel damage responsible for alveolar hemorrhage-necrosis; (iii) inhibiting the transition of endothelial and smooth muscle cells to mesenchymal cells in the pulmonary artery, preventing clotting and thrombotic complications., Discussion and Conclusion: If the ongoing trials presented herein should provide positive findings, the low cost, wide availability and temperature stability of PDE5 inhibitors could make them a major resource to combat COVID-19 in developing countries., (© 2020 American Society of Andrology and European Academy of Andrology.)
- Published
- 2021
- Full Text
- View/download PDF
46. Cortisol Circadian Rhythm and Insulin Resistance in Muscle: Effect of Dosing and Timing of Hydrocortisone Exposure on Insulin Sensitivity in Synchronized Muscle Cells.
- Author
-
Negri M, Pivonello C, Simeoli C, Di Gennaro G, Venneri MA, Sciarra F, Ferrigno R, de Angelis C, Sbardella E, De Martino MC, Colao A, Isidori AM, and Pivonello R
- Subjects
- Animals, Cells, Cultured, Humans, Hydrocortisone administration & dosage, Mice, Circadian Rhythm drug effects, Hydrocortisone metabolism, Hydrocortisone pharmacology, Insulin metabolism, Insulin Resistance, Muscle Cells drug effects, Muscle Cells metabolism
- Abstract
Introduction/aim: Circadian clock disruption is emerging as a risk factor for metabolic disorders, and particularly, alterations in clock genes circadian expression have been shown to influence insulin sensitivity. Recently, the reciprocal interplay between the circadian clock machinery and hypothal-amus-pituitary-adrenal axis has been largely demonstrated: the circadian clock may control the physiological circadian endogenous glucocorticoid (GC) secretion and action; GCs, in turn, are potent regulators of the circadian clock and their inappropriate replacement has been associated with metabolic impairment. The aim of the current study was to investigate in vitro the interaction between the timing-of-the-day exposure to different hydrocortisone (HC) concentrations and muscle insulin sensitivity., Methods: Serum-shock synchronized mouse skeletal muscle C2C12 cells were exposed to different HC concentrations resembling the circulating daily physiological cortisol profile (standard cortisol profile) and the circulating daily cortisol profile that reached in adrenal insufficient (AI) patients treated with once-daily modified-release HC (flat cortisol profile) and treated with thrice-daily conventional immediate-release HC (steep cortisol profile). The 24 h spontaneous oscillation of the clock genes in synchronized C2C12 cells was used to align the timing for in vitro HC exposure (Bmal1 acrophase, midphase, and bathyphase) with the reference times of cortisol peaks in AI patients treated with IR-HC (8 a.m., 1 p.m., and 6 p.m.). A panel of 84 insulin sensitivity-related genes and intracellular insulin signaling proteins were analyzed by RT-qPCR and Western blot, respectively., Results: The steep profile, characterized by a higher HC exposure during Bmal1bathyphase, produced significant downregulation in 21 insulin sensitivity-related genes including Insr, Irs1, Irs2, Pi3kca, and Adipor2, compared to the flat and standard profile. Reduced intracellular IRS1 Tyr608, AKT Ser473, AMPK Thr172, and ACC Ser79 phosphorylations were also observed., Conclusions: The current study demonstrated that late-in-the-day cortisol exposure modulates insulin sensitivity-related gene expression and intracellular insulin signaling in skeletal muscle cells., (© 2020 S. Karger AG, Basel.)
- Published
- 2021
- Full Text
- View/download PDF
47. Pancreatic Neuroendocrine Neoplasms: Does Sex Matter?
- Author
-
Muscogiuri G, Barrea L, Feola T, Gallo M, Messina E, Venneri MA, Faggiano A, and Colao A
- Subjects
- Biomarkers, Tumor metabolism, Female, Humans, Male, Prognosis, Sex Characteristics, Neuroendocrine Tumors pathology, Pancreatic Neoplasms pathology
- Abstract
Genetic and molecular disparities between men and women have a role in the differing incidence, pathophysiology, clinical signs, and treatment outcome of several cancers. Sex differences in cancer incidence are attributed to regulation at the genetic/molecular level and to sex hormones that in turn modulate gene expression in various cancers. Sex differences in the incidence of cancer, its aggressiveness, and the disease prognosis have been reported for several types of cancer but little is known for pancreatic neuroendocrine neoplasms (PNENs). The aim of this Opinion article is to provide an overview of sex differences in PNENs in terms of epidemiology, pathophysiology, treatment responses, prognosis, and survival. This overview might allow better tailoring of the management of PNENs., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
48. The Immune System in Cushing's Syndrome.
- Author
-
Hasenmajer V, Sbardella E, Sciarra F, Minnetti M, Isidori AM, and Venneri MA
- Subjects
- Animals, Humans, Interleukin-1 metabolism, Interleukin-6 metabolism, Cushing Syndrome metabolism, Immune System metabolism, Inflammation metabolism
- Abstract
Cushing's syndrome (CS), or chronic hypercortisolism, induces a variety of alterations in the immune system, often leading to severe clinical complications such as sepsis and opportunistic infections. Prolonged exposure to high levels of glucocorticoids (GC), changes in the circadian rhythm, and the comorbidities associated therewith all combine to cause profound changes in the immune profile of affected patients. While traditionally associated with generalized immune suppression, such changes actually comprise a much more complex scenario, sharing traits with chronic inflammatory disorders. Persistently increased levels of interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNFα) and adipose tissue infiltration by immune cells lead to a chronic, nonresolving, inflammatory state. The combination of low-grade inflammation and selectively impaired immune response is thought to play a major role in the pathogenesis of clinical complications of CS, including diabetes, lipodystrophy, visceral adiposity, atherosclerosis, osteoporosis, and cognitive impairment. This dysregulation also explains rebound phenomena when CS is treated, involving new clinical complications sustained by an excessive immune response and autoimmunity. The aim of this review is to summarize the available evidence on the immune system in chronic hypercortisolism, while describing the main mechanisms of immune derangement and their role in the increased mortality and morbidity seen in this complex disease. A better understanding of immune system alterations in CS could help improve risk stratification, offer novel biomarkers, and provide the basis for more tailored therapies and post-remission follow-up., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
49. Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective.
- Author
-
Muscogiuri G, Altieri B, Albertelli M, Dotto A, Modica R, Barrea L, Fanciulli G, Feola T, Baldelli R, Ruggeri RM, Gallo M, Guarnotta V, Malandrino P, Messina E, Venneri MA, Giannetta E, Ferone D, Colao A, and Faggiano A
- Subjects
- Female, Humans, Male, Middle Aged, Pancreas, Retrospective Studies, Diabetes Mellitus, Type 2, Neuroendocrine Tumors epidemiology, Pancreatic Neoplasms epidemiology
- Abstract
Purpose: Pancreatic neuroendocrine neoplasms (PNENs) are a group of clinically rare and heterogeneous tumors of the pancreas. Currently there are no studies investigating the gender difference in PNEN susceptibility. Thus, the purpose of this study was aimed at examining how gender shapes risk factors, clinicopathological features, and comorbidities in PNENs., Methods: The study design consisted of an Italian multicenter, retrospective study. The study included all consecutive patients with PNENs followed at the participating centers. Two hundred and twenty-nine patients (105 males,124 females, age 54 ± 0.98 years) with PNENs were enrolled at the participating centers. The clinicopathological features (age, gender, BMI, histology, tumor size, tumor grade, distant metastasis, hormonal function, and diagnostic circumstances), comorbidities (cardiovascular diseases (CVD), pancreatitis, type 2 diabetes (T2DM), and potential risk factors (smoking and drinking) were included in the analysis., Results: Females were slightly prevalent (54.15%). PNENs were diagnosed at younger age in females compared to males (p = 0.04). The prevalence of CVD was significantly higher in males than in females (p = 0.006). In the female group, the presence of T2DM was significantly associated with higher tumor grade (p = 0.04) and metastatic disease (p = 0.02). The proportion of smokers and alcohol drinkers was significantly higher in the male group (p < 0.001). No significant gender differences were detected regarding the other parameters included in the analysis., Conclusions: This study has identified gender differences of PNENs in terms of age at diagnosis, associated comorbidities, and potential risk factors. A gender-tailored approach could become a potential strategy to better understand the natural history of PNENs and improve the effectiveness of PNENs clinical management.
- Published
- 2020
- Full Text
- View/download PDF
50. COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency.
- Author
-
Isidori AM, Arnaldi G, Boscaro M, Falorni A, Giordano C, Giordano R, Pivonello R, Pofi R, Hasenmajer V, Venneri MA, Sbardella E, Simeoli C, Scaroni C, and Lenzi A
- Subjects
- Adrenal Insufficiency immunology, COVID-19, Consensus, Coronavirus Infections immunology, Humans, Italy, Pandemics, Pneumonia, Viral immunology, COVID-19 Drug Treatment, Adrenal Insufficiency complications, Adrenal Insufficiency drug therapy, Coronavirus Infections complications, Coronavirus Infections drug therapy, Glucocorticoids therapeutic use, Hormone Replacement Therapy methods, Pneumonia, Viral complications, Pneumonia, Viral drug therapy, Steroids therapeutic use
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.